CannabisNewsBreaks Archive - Page 24 of 429

TuesdayJun 20, 2023 2:14 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands IP Portfolio with Four New Patents

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced its receipt of four newly granted patents. The company secured two new Canadian patents, its 18th in its patent family No. 1: Food and Beverage Compositions Infused with Lipophilic Active Agents and Methods of Use Thereof, and No. 8 in its: Compositions Infused with Nicotine Compounds and Methods of Use Thereof. Lexaria was also granted two new U.S. patents under its patent family No. 21. The first being for Pharmaceutical Compositions and Methods for Treating Hypertension, as well as the second being for Compositions and Methods…

FridayJun 16, 2023 1:51 pm

CannabisNewsBreaks – Lift Events Partners with Arcview Group for Upcoming US Cannabis, Investment Event

Lift Events announced a new partnership with the Arcview Group as it anticipates its upcoming Lift San Francisco event, slated for Aug. 3–4, 2023. The company announced that the Lift Cannabis Business Conference, slated for Aug. 3, will be a combined event with a new Investment Summit presented in partnership with the Arcview Group, a recognized pioneer in cannabis and hemp industry investment content. According to the announcement, the “game-changing” partnership will prioritize social justice and responsibility, with the Arcview Group providing a broad spectrum of programs and services across a vertically integrated organization. In addition, the Lift San Francisco…

FridayJun 16, 2023 11:52 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports on Promising Results from Diabetes Animal Study

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is releasing additional findings from its DIAB-A22-1 study, a diabetes animal study designed to evaluate the company’s proprietary DehydraTECH-CBD. DehydraTECH is a patented drug-delivery formulation and processing platform technology developed by Lexaria. The company noted that in addition to the three positive outcomes reported earlier — weight loss in obese diabetic-conditioned animals and improved triglyceride and cholesterol levels — the study has indicated a reduction in blood glucose levels and improvements in kidney function. These results were gathered after the company undertook a further round of analysis to explore additional study…

MondayJun 12, 2023 1:12 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Experienced Financial Professional as New CFO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of a new chief financial officer. Effective immediately, Mike Shankman will serve as outsourced CFO. An experienced accounting and finance professional, Shankman has held senior positions with companies in the biotechnology, medical devices and software-as-a-service industries. As a consultant with NOW CFO, one of his current clients is a publicly traded clinical-stage biopharmaceutical company. Former clients include a medical device maker for which Mike collaborated with independent auditors and investment bankers through the completion of an initial public offering. The client began trading on…

FridayJun 09, 2023 10:42 am

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Portfolio of Worldwide Patents

Lexaria Bioscience Corp. (NASDAQ: LEXX), the global leader in enhancing the speed and efficiency of orally delivered fat-soluble active molecules and drugs through its patented DehydraTECH(TM) technology, recently announced it had received notification of four newly awarded or allowed patents. “The new patents will add to Lexaria’s growing portfolio and, upon award, will bring the total number of patents granted worldwide to 32, with several more pending,” a recent article reads. “Lexaria’s new patent in Japan is under Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Agents. This patent is the fifth awarded in Japan, strengthening the company’s growing…

TuesdayJun 06, 2023 2:54 pm

CannabisNewsBreaks – IGC Pharma Inc. (NYSE American: IGC) Receives Notice of Allowance for Patent on IGC-501

IGC Pharma (NYSE American: IGC) today announced its receipt of a Notice of Allowance from the Commissioner of Patents, Canada, for its patent filing on the use of cannabinoids in the treatment of seizures (“IGC-501”). The formulation additionally received an intent to grant from the European Patent Office. With these and a previous award, the formulation for treating seizures is protected in the U.S., Canada and certain European countries. IGC provided animal data (dogs) on the reduction in the number of seizures by using a combination of cannabidiol (“CBD”) and phenobarbital versus either alone. The company intends to pursue the…

MondayJun 05, 2023 12:48 pm

CannabisNewsBreaks – IGC Pharma Inc.’s (NYSE American: IGC) Advisor and Inventor of TGR-63 Receives National Technology Award

IGC Pharma (NYSE American: IGC) today announced recognition of its advisor, Professor T. Govindaraju, the inventor of the investigational Alzheimer’s drug candidate, TGR-63. According to the announcement, Govindaraju received the Government of India-instituted National Technology Award (Translational Research) for “Outstanding Contribution in Commercializing Innovative Indigenous Technologies” from the Minister of State for Science and Technology and Earth Sciences. The Department of Science and Technology (“DST”)-Technology Development Board (“TDB”), Government of India presented Professor Govindaraju with the prestigious award on May 14, 2023. The awards acknowledge excellence and success in the commercialization of technology indigenous to India, and Professor Govindaraju is…

ThursdayJun 01, 2023 12:14 pm

CannabisNewsBreaks – ECGI Holdings Inc. (ECGI) Closes Acquisition of East West Pharma Group

ECGI Holdings (OTC: ECGI), D/B/A Elite Cannabis Group Incorporated, is a Nevada-based portfolio company pivoting into the legal cannabis and cannabinoid marketplace. The company today announced the closing of its acquisition of East West Pharma Group, Inc. ("EWPG"), a Wyoming corporation with specialized equipment and experienced personnel, including leaders in the cannabinoid extraction and product manufacturing space. “We couldn’t be more excited to have this deal closed and in the books as we look ahead to an exciting summer,” said ECGI CEO Danny Wong . “The cannabis market has been recovering, with spot prices up over 20% in the past…

ThursdayJun 01, 2023 11:41 am

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids, today announced that results from a neurodegenerative disease study were presented in a scientific poster at the Canadian Neuroscience Meeting in Montreal from May 28-31, 2023. The InMed sponsored research demonstrated the ability of a specific rare cannabinoid (“pCBx”) in InMed’s 900 Series library of potential candidates that reduces amyloid toxicity and tau protein expression while enhancing neuronal cell growth and neuritogenesis markers in vitro. These are all considered to be important targets in the potential treatment of neurodegenerative diseases such as Alzheimer’s.…

FridayMay 26, 2023 11:54 am

CannabisNewsBreaks – Bright Green Corporation (NASDAQ: BGXX) Announces Pricing of $3.5M Private Placement

Bright Green (NASDAQ: BGXX) is one of the few companies selected by the U.S. government to grow, manufacture and sell, legally under federal and state laws, cannabis and cannabis-related products for research, pharmaceutical applications and affiliated export. The company recently announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,684,210 shares of common stock and warrants to purchase up to 3,684,210 shares of common stock, at a purchase price of $0.95 per share and accompanying warrant. Bright Green expects approximately $3.5 million in gross proceeds from the private placement. EF Hutton, division…

News and publishing service for cannabis related companies

Contact us: 512.354.7000

CannabisNewsBreaks